EAM Investors LLC Has $3.93 Million Stock Position in GeneDx Holdings Corp. (NASDAQ:WGS)

EAM Investors LLC raised its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 56.3% in the fourth quarter, HoldingsChannel reports. The fund owned 51,183 shares of the company’s stock after acquiring an additional 18,446 shares during the period. EAM Investors LLC’s holdings in GeneDx were worth $3,934,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. William Blair Investment Management LLC bought a new stake in GeneDx in the 4th quarter valued at $51,496,000. Zweig DiMenna Associates LLC bought a new stake in shares of GeneDx in the fourth quarter valued at about $23,788,000. Raymond James Financial Inc. acquired a new position in shares of GeneDx in the fourth quarter valued at about $20,371,000. Invesco Ltd. increased its position in GeneDx by 4,382.2% during the fourth quarter. Invesco Ltd. now owns 255,351 shares of the company’s stock worth $19,626,000 after acquiring an additional 249,654 shares during the period. Finally, Next Century Growth Investors LLC raised its stake in GeneDx by 121.1% in the 4th quarter. Next Century Growth Investors LLC now owns 312,014 shares of the company’s stock worth $23,981,000 after purchasing an additional 170,901 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on WGS. The Goldman Sachs Group raised their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. TD Cowen increased their price target on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.33.

GeneDx Stock Performance

Shares of GeneDx stock opened at $102.22 on Wednesday. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The company has a market cap of $2.87 billion, a PE ratio of -52.15 and a beta of 1.93. The company has a 50 day moving average of $91.91 and a 200-day moving average of $78.94. GeneDx Holdings Corp. has a 1-year low of $8.63 and a 1-year high of $115.60.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. As a group, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insider Activity at GeneDx

In related news, CFO Kevin Feeley sold 402 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $90.05, for a total transaction of $36,200.10. Following the sale, the chief financial officer now owns 5,044 shares of the company’s stock, valued at $454,212.20. This trade represents a 7.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Katherine Stueland sold 46,594 shares of the company’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $89.62, for a total value of $4,175,754.28. Following the completion of the transaction, the chief executive officer now directly owns 1,720 shares of the company’s stock, valued at approximately $154,146.40. The trade was a 96.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 138,780 shares of company stock valued at $12,907,437 over the last ninety days. 27.30% of the stock is owned by corporate insiders.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.